Precursor T lymphoblastic lymphoma (TLBL) is a highly aggressive lymphoma. While lymphatic antigen expression is the major immunophenotype, quite a few patients present mixed series expression (such as myeloid antigen). Currently, there are numerous studies on the association of myeloid antigen expression with clinical features and outcomes in acute lymphoblastic leukemia (ALL), yet the results are conflicting. In the 1990s, most investigators thought that ALL patients with myeloid antigen expressions were expected to have a poor prognosis, especially in adults. But in recent years, it was found in many studies that myeloid antigen expression in ALL was not correlated with clinical outcomes. Lymphoblastic lymphoma and acute leukemia are the same entity with different clinical features, and reports of lymphoblastic lymphoma with myeloid antigen expressions are rare. Our study was aimed to describe the features of myeloid antigen expressions in TLBL patients, and analyze their associations with biological characteristics, shortterm therapeutic efficacy and prognosis. Of the 45 patients, 38 received only chemotherapy, five were treated with chemotherapy and whole brain radiotherapy, and two patients were treated with chemotherapy and autologous stem cell transplantation. Patients under 18 years of age were subjected to TNHLBFM90 regimen and those older than 18 to high intensity regimens such as EPOCH, HyperCAVD, and combined chemotherapy using prophylactic intrathecal injection. One child failed in the induction therapy because of disease progression.
Followup was conducted until June 1, 2009 by medical history tracing, telephone contact and written correspondences. .
For the patients treated with BFM90 regimen, shortterm efficacy was evaluated after induction chemotherapy (Ia+Ib); for those treated with EPOCH or other regimens, shortterm efficacy was evaluated after two treatment cycles. Efficacies were evaluated according to the revised version of International Malignant Lymphoma Evaluation Criteria: complete remission (CR), partial remission (PR), stable disease (SD), progressive disease (PD), response rate (RR) = CR + PR, no response (NR) = SD + PD. SPSS16.0 software was used for analysis. Myeloid antigen expression of patients with different clinicopathologic characteristics were compared using Chisquare test. Efficacy was evaluated based on the survival data by KaplanMeier method. Logrank was used for the univariate analysis and Cox model was used for multivariate analysis. Significant difference was defined when < 0.05.
Of the 45 patients, all expressed CyCD3 and CD7, 37 (82.2%) expressed TdT, 35 (77.8%) expressed CD5, 24 (53.3%) expressed CD3 and 19 (42.2% ) expressed CD34; 18 (40.0% ) had concomitant myeloid antigen expression, including 12 (26.7% ) expressing CD13, nine (20.0% ) expressing CD33, and three (6.7% ) expressing both CD13 and CD33. CD34 was expressed at a higher level in My (+) group than those in My () group (66.7% vs. 25.9%, = 0.0007).
Myeloid antigen expression was correlated with the LDH levels of patients with TLBL in the initial evaluation ( < 0.05). Patients with LDH < 500 U/L showed high myeloid antigen expression. Myeloid antigen expression did not correlate with gender, age, mediastinal mass, large mass, number of extranodular lesions, B symptoms, PS score, count of leukocyte and platelet, bone marrow blast proportion ( > 0.05) ( Table 1 ).
The patients were followedup till June 1, 2009 with a median period of 27 months (7110 months). Fourteen patients died, 29 were still under followup and two were lost to followup. Treatment efficacy was evaluable in 45 patients. The CR rate of My () group was significantly lower than that of My (+) group (38.8% vs. 70.3% ; = 0.028); ORR of My (+) group was lower than that of My() group (83.3% vs. 96.2%; = 0.136).
The 2year overall survival rate of the whole group was 68.4%, and the survival rate of My () group was significantly higher than that of My(+) group (78.7% vs. 51.9%; = 0.036; Figure 1 ).
Of the 45 patients, 28 were under 18 years old and 17 were more than 18 years old. Among the patients of under 18 years old, the CR rate of My (+) and My() groups were similar (87.5% vs. 95.0% , = 0.746), and the 2year survival rates were not significantly different (75.0% vs. 86.1% ; = 0.484, Figure 2 ). Among the patients of more than 18 years old, the CR rate was significantly higher in My() group than in My(+) group (42.9% vs. 10.0% ; = 0.043), so was the 2year survival rate (62.5% vs. 27.8%; = 0.047, Figure 3 Factors of 臆 0.1 in univariate analysis were introduced into Cox multivariate analysis, showing that age ( < 0.001) and positive myeloid antigen expression ( = 0.024) were independent prognostic risk factors.
TLBL is a highly invasive and progressive lymphatic malignant tumor. LBL accounts for 25% 30% of nonHodgkin's . The effects of myeloid antigen expression on clinical characteristics and prognosis of TLBL were debated in previous studies. The biological activity of LBL is similar to that of acute lymphatic leukemia (ALL), and WHO lymphoma classification system (2000) classified LBL and ALL into the same type (TLBL/ALL). Lymphatic antigen expression is the primary immunophenotype of LBL, while some LBL may present mixed series expressions such as concomitant myeloid antigen expression. It is reported that myeloid antigen expression accounts for 10% 43% of the ALL, without significant differences between BALL and T ALL [2] . Chang . [3] reported that positive CD33 was found most frequently with a positive rate of 15.7% , accounting for 72.7% of My(+) cases; while other studies [4, 5] showed that CD13 was most common with a positive rate of 13.0% 17.4% ), accounting for 69.4%80.5% of My(+) cases. In our study, 40.0% of TLBL had concomitant myeloid antigen expression, which was consistent with other studies. Myeloid antigens were predominantly CD13 and CD33, without significant difference ( > 0.05).
Most studies showed that myeloid antigen expression was not associated with clinical characteristics when first diagonsed [4, 6] . Xicoy . [6] reported that myeloid antigen expression of TALL was not significantly associated with its clinical characteristics and biological activities. Preti . [7] found that myeloid antigen positive ALL was typically characterized by increased ALP level, thrombocytopenia, leukocytosis and older age. TLBL is manifested by mediastinal mass, lymphadenopathy and involvement of bone marrow and central nervous system (CNS). The present study showed that myeloid antigen expression was not associated with gender, age, mediastinal mass, large mass, number of extranodular lesions, B symptoms, PS scores, count of leukocyte and platelet, bone marrow blasts proportions ( > 0.05), but high levels of LDH in My (+) group were seen less frequently than in My() group.
In recent years, treatment of adolescent LBL with intensive regimens similar to that for ALL has achieved favorable outcomes with a fiveyear eventfree survival (EFS) of 70% 90% [8] . Adult LBL was treated with intensive chemotherapy regimens such as HyperCVAD and EPOCH, achieving a shortterm CR of 70% 85% [9] . However, the fiveyear survival rate of highrisk children and LBL adult was lower than 50% , and maintenance of remission was short [10] . The key issue of improving LBL outcome is how to determine highrisk patients to initiate appropriate treatment. Presently, there were numerous studies focusing on the relationship between myeloid antigen expression and ALL outcomes, while its association with LBL is rarely investigated. Because of the disparities of myeloid antigen expression criteria, treatment regimens and timing of efficacy evaluations, the results are difficult to interpret. Most investigators found that myeloid antigen expression did not influence the early CR rate, persistent remission time and prognosis of ALL patients [1113] . Vitale . [11] reported that myeloid antigen expression was not correlated with remission rate and remission duration of ALL. Drexler . [14] found that myeloid antigen expression could influence the early remission rate and progressionfree survival (PFS) in adult ALL, while this has never been tested in children. Pituch . [15] reported that myeloid antigen expression in children's ALL was correlated with multidrug resistance molecule (MDR) and CD34 expression rate, and MDR expression could inhibit in vitro apoptosis of lymphocytes indirectly. The remission duration of My (+) ALL was significantly longer than those of My (). The present study found that the early remission rate of My (+) patients was significantly lower than My () patients ( = 0.028). Further subgroup analysis indicated that positive myeloid antigen expression did not influence early remission rate in children (87.5% vs. 95.0%; = 0.746); while early remission rate of adult patients was significantly lower in My (+) group than in My () group (10.0% vs. 42.9%; = 0.043), which was consistent with some previous studies [14] . Our results suggest that early remission is difficult to achieve in adult patients with positive myeloid antigen expression, while we didn't observe the same results in the children.
The 5year survival rate and relapse rate after remission of My (+) ALL were not significantly different from My () ALL [1618] . The total and diseasefree survival rates were not affected by myeloid antigen expression in children with ALL in the study of Unal . [16] . However, My (+) patients were more likely to be categorized into high risk group and received more intense regimens. Yanenel . [19] suggested that myeloid expression in adult may result in better longterm survival. Drexler . [14] found that myeloid antigen expression was not a prognostic factor in children with lymphatic leukemia, but a prognostic risk factor in adult. Followup duration of our study was short (27 months) and only the 2year survival was analyzed. The 2year survival rate of My () group was significantly higher than that of MY (+) group (78.7% vs. 51.9% ; = 0.036), indicating the importance of myeloid antigen expression. Further analysis of subgroups classified by age showed that the 2year total survival rate of children was not influenced by myeloid expression (75.0% vs. 86.1% ; = 0.484), but the 2year survival rate of My (+) group was significantly lower than that of adult My() group ( = 0.047). Univariate analysis showed that myeloid expression ( = 0.036) and age ( = 0.001) were prognostic risk factors of TLBL, and gender, stage, large mass, mediastinal mass and CD34 expression were not associated with the prognosis. Multivariate analysis showed that myeloid expression and age were independent prognostic risk factors of TLBL ( = 0.002, 0.024), which do not include gender. ( > 0.05). Results of our study suggest that the survival rate of adult TLBL with myeloid expression is significantly lower than those with negative myeloid expression, while this phenomenon is not observed in children probably because these children have received high intense chemotherapy regimens as adopted in ALL [1] . However, the adult sample was small in this study and treatment regimens were different, which remarkably compromised the statistical power. And further investigations with larger sample size are needed.
In conclusion, our study suggests that the survival rate of adult TLBL patients with myeloid expression is significantly lower than those with negative myeloid expression, while this phenomenon is not observed in the children. 
